HPLC Method for the Analysis of Tirzepatide in Pharmaceutical Formulation Mounjaro on Primesep B Column
https://sielc.com/hplc-method-for-analysis-tirzepatideChromatogram
Description
Tirzepatide is a synthetic peptide that functions as a dual agonist of the GLP-1 and GIP receptors. It is used in the treatment of type 2 diabetes and obesity. By mimicking the actions of both glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), tirzepatide enhances insulin secretion, reduces blood sugar levels, promotes satiety, and aids in weight loss.
Tirzepatide can be retained and analyzed using the Primesep B stationary phase column. The analysis utilizes an gradientc method with a simple mobile phase consisting of water, acetonitrile (MeCN), and TFA. Detection is performed using UV at 280 nm.
Method Parameters
| Mobile Phase | Gradient MeCN – 30-70%, 10 mn |
|---|---|
| Buffer | TFA – 0.1% |
| Flow Rate | 0.5 ml/min |
| Detection | UV 280 nm |
| LOD | 24 ppb |
| Class of Compounds | GLP-1 Receptor Agonist |
| Analyzing Compounds | Tirzepatide |
HPLC Column Used
Primesep B, 3.2 x 50 mm, 5 µm, 100 A, dual ended